Forum für Wissenschaft, Industrie und Wirtschaft

Hauptsponsoren:     3M 


Immunity drives cancer into permanent growth arrest

Martin Röcken and his team at the Department of Dermatology, Eberhard Karls University Tuebingen, found that anti-cancer immunity is capable of driving cancers and single cancer cells into a permanent growth arrest (1).

Scientifically this permanent growth arrest is called senescence (2, 3). As complete cancer eradication is normally not feasible, deadly metastases normally result from surviving and regrowing cancer cells. The new data now explain, how immunity and immunotherapies can efficiently control surviving cancer cells and thus protect from cancer and metastases (1, 4).

Fig. 1: In red, the expression of a senescence marker in former proliferating melanoma cells that underwent growth arrest. Here, senescence occurred in the context of melanoma regression induced by a natural anti-melanoma immune response. In brown, pigment bearing cells.
University Hospital Tübingen

„The major goal of cancer therapy is the eradication, if possible of all cancer cells. Yet, we have learned over the past 50 years that some cancer cells survive even the most aggressive, cancer cell-killing therapy. It is assumed that such surviving cancer cell restore the cancer and cause the deadly metastases. This casts doubt on a therapeutic strategies that focus exclusively on cancer cell killing. Therefore, it was repeatedly postulated that, in addition to cancer cell killing, other (immune-) mechanisms are needed to control cancer (5, 6, 7).“ – as summarized by Professor Röcken.

The Tuebingen research team uncovered a critical, so far unknown immune mechanism that allows to permanently paralyze growing cancer cells. They showed for the first time that immune responses can cause a permanent growth arrest in cancers and also in single cancer cells (1). Scientifically this permanent growth arrest is termed senescence (2, 3).

Even under conditions where the immune system cannot kill the cancer, the two cytokines interferon (IFN) and tumor necrosis factor (TNF), may drive cancers into senescence. Thus, senescence induction causes a state, where ‚the cancer sleeps well controlled in his host’. This was first shown in an islet cancer of the pancreas (1, 4).

The same two cytokines, IFN and TNF, can drive a large number of mouse and human cancer cells into senescence. Clinically, this has two major consequences: Immune-induced senescence (figure 1) is obviously a physiological mechanism that contributes to the natural cancer control in humans (1). On the other side, recent data from cancer immune therapy suggest that the therapy is primarily efficient under conditions where the immune therapy causes permanent growth arrest of the metastases (8, 9).

Two mediators that are long known in cancer and infection immunology turn into the focus: interferon (IFN) and tumor necrosis factor (TNF). Many clinicians and researchers tried to destroy cancer and cancer-supplying vessels – like the Tuebingen researchers. Surprisingly, the Tuebingen group found that a certain combination of IFN and TNF protects mice from the development of islet cancers in the pancreas.

In the animals induction of senescence resulted in unexpectedly long protection from cancer (4). Even more important: when isolated from cancer prone animals, the ‘senescent cancer cells’ remained growth arrested without any further therapy, even when transferred into immune deficient, healthy mice. Thus, the senescent cancer cells had lost the aggressive behavior that characterizes cancer and remained well controlled (1).

This new therapeutic strategy offers the opportunity to develop new cancer immunotherapy that should be less aggressive, with relatively few side effects but highly efficient. Professor Rocken: „It is likely that in the future we will not primarily try to destroy cancer with ever more toxic regimen; instead we will focus on strategies that restore the body’s immune control over cancers “.

Media contact

Eberhard Karls University Tuebingen
Department of Dermatology
Prof. Dr. Martin Röcken
Liebermeisterstr. 25, 72076 Tuebingen
Tel. +49 (0)7071 29 84574
Fax +49 (0)7071/29 5450
1. Braumüller, H, Thomas Wieder, T, Brenner, E, Aßmann, S, Hahn, M, Alkhaled, M, Schilbach, K, Essmann, F, Kneilling, M, Griessinger, C, Ranta, F, Ullrich, S, Mocikat, R, Braungart, K, Mehra, T, Fehrenbacher, B, BerdeL, J, Meier, F, van den Broek, M, Häring, HU, Handgretinger, R, Quintanilla-Martinez, L, Fend, F, Pesic, M, Bauer, J, Zender, L, Schaller, M, Schulze-Osthoff, K, Röcken, M. T-helper-1-cell cytokines drive cancer into senescence.

Nature (online 04.02.2013). doi:10.1038/nature11824.

2. Michaloglou, C. et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436, 720-724 (2005).
3. Braig, M. et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436, 660-665 (2005).
4. Müller-Hermelink, N. et al. TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell 13, 507-518 (2008).
5. Sporn, MB. The war on cancer. The Lancet 347, 1377-1381 (1996).
6. Gatenby, RA. A change of strategy in the war on cancer. Nature 459, 508-509 (2009).

7. Röcken, M. Early tumor dissemination, but late metastasis: insights into tumor dormancy. J. Clin. Invest. 120, 1800-1803 (2010).

8. Walter S, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat. Med. 18, 1254–1261 (2012).

9. Brahmer JR, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 366; 2455-2465 (2012).

Dr. Ellen Katz | idw
Further information:

More articles from Health and Medicine:

nachricht An ounce of prevention: Research advances on 'scourge' of transplant wards
28.08.2015 | University of Wisconsin-Madison

nachricht Hypoallergenic parks: Coming soon?
27.08.2015 | American Society of Agronomy

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: OU astrophysicist and collaborators find supermassive black holes in quasar nearest Earth

A University of Oklahoma astrophysicist and his Chinese collaborator have found two supermassive black holes in Markarian 231, the nearest quasar to Earth, using observations from NASA's Hubble Space Telescope.

The discovery of two supermassive black holes--one larger one and a second, smaller one--are evidence of a binary black hole and suggests that supermassive...

Im Focus: Optische Schalter - Lernen mit Licht

Einem deutsch-französischen Team ist es gelungen, einen lichtempfindlichen Schalter für Nervenzellen zu entwickeln. Dies ermöglicht neue Einblicke in die Funktionsweise von Gedächtnis und Lernen, aber auch in die Entstehung von Krankheiten.

Lernen ist nur möglich, weil die Verknüpfungen zwischen den Nervenzellen im Gehirn fortwährend umgebaut werden: Je häufiger bestimmte Reizübertragungswege...

Im Focus: What would a tsunami in the Mediterranean look like?

A team of European researchers have developed a model to simulate the impact of tsunamis generated by earthquakes and applied it to the Eastern Mediterranean. The results show how tsunami waves could hit and inundate coastal areas in southern Italy and Greece. The study is published today (27 August) in Ocean Science, an open access journal of the European Geosciences Union (EGU).

Though not as frequent as in the Pacific and Indian oceans, tsunamis also occur in the Mediterranean, mainly due to earthquakes generated when the African...

Im Focus: Membranprotein in Bern erstmals entschlüsselt

Dreidimensionale (3D) Atommodelle von Proteinen sind wichtig, um deren Funktion zu verstehen. Dies ermöglicht unter anderem die Entwicklung neuer Therapieansätze für Krankheiten. Berner Strukturbiologen ist es nun gelungen, die Struktur eines wichtigen Membranproteins zu entschlüsseln – dies gelingt relativ selten und ist eine Premiere in Bern.

Membranproteine befinden sich in den Wänden der Zellen, den Zellmembranen, und nehmen im menschlichen Körper lebenswichtige Funktionen wahr. Zu ihnen gehören...

Im Focus: Quantenbeugung an einem Hauch von Nichts

Die Quantenphysik besagt, dass sich auch massive Objekte wie Wellen verhalten und scheinbar an vielen Orten zugleich sein können. Dieses Phänomen kann nachgewiesen werden, indem man diese Materiewellen an einem Gitter beugt. Eine europäische Kollaboration hat nun erstmals die Delokalisation von massiven Molekülen an einem Gitter nachgewiesen, das nur noch eine einzige Atomlage dick ist. Dieses Experiment lotete die technischen Grenzen der Materiewellentechnologie aus und knüpft dabei an ein Gedankenexperiment von Bohr und Einstein an. Die Ergebnisse werden aktuell im Journal "Nature Nanotechnology" veröffentlicht.

Die quantenmechanische Wellennatur der Materie ist die Grundlage für viele moderne Technologien, wie z. B. die höchstauflösende Elektronenmikroskopie, die...

Alle Focus-News des Innovations-reports >>>



im innovations-report
in Kooperation mit academics

Gravitationswellen im Einsteinjahr

28.08.2015 | Veranstaltungen

Strömungen in industriellen Anlagen sichtbar gemacht

28.08.2015 | Veranstaltungen

Konzepte gegen Fachkräftemangel: Demografiekonferenz in Halle

27.08.2015 | Veranstaltungen

Weitere VideoLinks >>>
Aktuelle Beiträge

Siemens an der Sicherheit: Lösungen für jede Anforderung

28.08.2015 | Messenachrichten

Biofabrikation von künstlichen Blutgefäßen mit Laserlicht

28.08.2015 | Biowissenschaften Chemie

Forscher entwickeln Methode zur Manipulation von Molekülen

28.08.2015 | Physik Astronomie